<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410525</url>
  </required_header>
  <id_info>
    <org_study_id>B7871003</org_study_id>
    <nct_id>NCT02410525</nct_id>
  </id_info>
  <brief_title>A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning</brief_title>
  <official_title>A Phase 1, Open-label, 3-period, Randomized, Partially Fixed Sequence, 2-way Crossover Study With A Microdose Of [11c]Pf-06427878 Administered With And Without Two Non-radioactive Doses Of Pf-06427878 To Characterize Tissue Distribution Using Positron Emission Tomography In Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, radioactive PF-06427878 will be administered, through a vein, alone and with 2
      different oral doses of non-radioactive PF-06427878 to healthy, adult, male subjects.
      Positron emission tomography will be used to characterize tissue distribution. The study will
      also characterize how the study drug behaves in the body, its safety, and how the body
      tolerates it.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent injected radioactivity (per gram) over time in the liver</measure>
    <time_frame>All Periods;Day 1;0-120min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent injected radioactivity (per gram) over time in the plasma</measure>
    <time_frame>All Periods;Day 1;0hr,1,2,3,4,5,5.5,6,6.5,7,8,9,10,12,15,20,25,30,40,50,60,75,90,105,120min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative radioactivity in liver versus plasma</measure>
    <time_frame>All Periods;Day 1;0hr,1,2,3,4,5,5.5,6,6.5,7,8,9,10,12,15,20,25,30,40,50,60,75,90,105,120min</time_frame>
    <description>Ratio of AUC of percent injected radioactivity (per gram) over time in liver to AUC of percent injected radioactivity (per gram) over time in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the gall bladder, if this region is identifiable</measure>
    <time_frame>All Periods;Day 1;0-2hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of parent in plasma over time</measure>
    <time_frame>All Periods;Day 1;0hr,1,2,3,4,5,5.5,6,6.5,7,8,9,10,12,15,20,25,30,40,50,60,75,90,105,120min</time_frame>
    <description>Parent is study drug PF-06427878</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: AUClast, as data permit</measure>
    <time_frame>Period 1;Day 1;0,3,5,15,30,60,90,120,135min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: AUClast, as data permit.</measure>
    <time_frame>Periods 2 &amp; 3;Day 1;prebreakfast,-90,-60,0,120min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the biliary tree, if this region is identifiable</measure>
    <time_frame>All Periods;Day 1;0-2hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the abdominal fat, if this region is identifiable</measure>
    <time_frame>All Periods;Day 1;0-2hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the kidney, if this region is identifiable</measure>
    <time_frame>All Periods;Day 1;0-2hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the urinary bladder, if this region is identifiable</measure>
    <time_frame>All Periods;Day 1;0-2hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the thigh muscle, if this region is identifiable</measure>
    <time_frame>All Periods;Day 1;0-2hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: AUCinf, as data permit</measure>
    <time_frame>Period 1;Day 1;0,3,5,15,30,60,90,120,135min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: Cmax, as data permit</measure>
    <time_frame>Period 1;Day 1;0,3,5,15,30,60,90,120,135min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: Tmax, as data permit</measure>
    <time_frame>Period 1;Day 1;0,3,5,15,30,60,90,120,135min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: t½, as data permit</measure>
    <time_frame>Period 1;Day 1;0,3,5,15,30,60,90,120,135min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: CL, as data permit</measure>
    <time_frame>Period 1;Day 1;0,3,5,15,30,60,90,120,135min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: Vss, as data permit</measure>
    <time_frame>Period 1;Day 1;0,3,5,15,30,60,90,120,135min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: Vss, as data permit.</measure>
    <time_frame>Periods 2 &amp; 3;Day 1;prebreakfast,-90,-60,0,120min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: AUCinf, as data permit.</measure>
    <time_frame>Periods 2 &amp; 3;Day 1;prebreakfast,-90,-60,0,120min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: Cmax, as data permit.</measure>
    <time_frame>Periods 2 &amp; 3;Day 1;prebreakfast,-90,-60,0,120min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: Tmax, as data permit.</measure>
    <time_frame>Periods 2 &amp; 3;Day 1;prebreakfast,-90,-60,0,120min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: t½, as data permit.</measure>
    <time_frame>Periods 2 &amp; 3;Day 1;prebreakfast,-90,-60,0,120min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of PF-06427878: CL/F, as data permit.</measure>
    <time_frame>Periods 2 &amp; 3;Day 1;prebreakfast,-90,-60,0,120min</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[11C]PF-06427878</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of [11C]PF-06427878 in Periods 1, 2 and 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06427878 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 10 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06427878 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 600 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]PF-06427878</intervention_name>
    <description>Single administration via intravenous infusion of 20 ug [11C]PF-06427878 on Day 1 of all 3 Periods</description>
    <arm_group_label>[11C]PF-06427878</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06427878 10 mg</intervention_name>
    <description>Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration</description>
    <arm_group_label>PF-06427878 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06427878 600 mg</intervention_name>
    <description>Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration</description>
    <arm_group_label>PF-06427878 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy males

          -  body mass index 17.5-30.5 kg/m2 ; body weight &gt;50 kg

          -  signed and dated informed consent document

          -  willing and able to comply with study requirements

        Exclusion Criteria:

          -  tobacco/nicotine containing products &gt; equivalent of 5 cigarettes per day

          -  history of cumulative ionizing radiation exposure in the past year, including
             anticipated exposure in this study, and subjects with current, past or anticipated
             exposure to radiation in the workplace

          -  severe claustrophobia

          -  unable to lie still for the required period to acquire images
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anylan Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperlipidemia</keyword>
  <keyword>positron emission tomography</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

